In preclinical models of myeloproliferative neoplasms, a subclass of hematological cancer, our recent work has provided evidence on the pathogenic role of bone marrow Nestin+ cell alterations, and the promising therapeutic value of their targeting [51]. This evidence concerns the gene NES and myeloproliferative disorder.